Desoxycorticosterone acetate - Generic Drug Details

What are the generic drug sources for desoxycorticosterone acetate and what is the scope of patent protection?

Desoxycorticosterone acetate is the generic ingredient in two branded drugs marketed by Organon Usa Inc and Novartis, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for desoxycorticosterone acetate.

Summary for desoxycorticosterone acetate

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	90
DailyMed Link:	desoxycorticosterone acetate at DailyMed

Medical Subject Heading (MeSH) Categories for desoxycorticosterone acetate

Mineralocorticoids

US Patents and Regulatory Information for desoxycorticosterone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PERCORTEN	desoxycorticosterone acetate	PELLET;IMPLANTATION	005151-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Organon Usa Inc	DOCA	desoxycorticosterone acetate	INJECTABLE;INJECTION	001104-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Desoxycorticosterone Acetate: Market Dynamics and Financial Trajectory

Last updated: February 18, 2026

Desoxycorticosterone acetate (DOCA) is a synthetic corticosteroid with mineralocorticoid and glucocorticoid activity. Its primary clinical application is in the management of adrenal insufficiency, particularly Addison's disease, and in the treatment of certain electrolyte imbalances. The market for DOCA is characterized by its established use in a niche therapeutic area, with production concentrated among a limited number of manufacturers. The financial trajectory is influenced by factors such as the prevalence of adrenal disorders, generic competition, and pricing strategies.

What is the Current Market Size and Growth Projection for Desoxycorticosterone Acetate?

The global market for desoxycorticosterone acetate is a segment within the broader corticosteroid market, which itself is substantial. Precise, up-to-the-minute market size figures for DOCA alone are not always readily available due to its specialized nature and inclusion in broader pharmaceutical classifications. However, industry analysis indicates a stable to modestly growing market. The Compound Annual Growth Rate (CAGR) for the global corticosteroid market, which DOCA contributes to, has been projected in the range of 4% to 6% for the period between 2023 and 2028 [1]. This growth is driven by increasing diagnosis rates of adrenal insufficiency and autoimmune diseases, as well as the expanding geriatric population, which is more susceptible to such conditions.

The specific market size for DOCA is estimated to be in the tens of millions of U.S. dollars annually. This is a mature market, meaning significant, rapid expansion is unlikely. Instead, growth will primarily stem from consistent demand for its established therapeutic benefits.

Who are the Key Manufacturers and Their Market Share in Desoxycorticosterone Acetate Production?

The production of desoxycorticosterone acetate is concentrated among a few key pharmaceutical companies, reflecting the specialized nature of its manufacturing and regulatory landscape. These manufacturers often produce a range of steroid-based therapeutics. While precise, publicly disclosed market share data for DOCA is scarce, major players in the corticosteroid synthesis space are known to include:

• Pfizer Inc.: A global pharmaceutical giant with a broad portfolio that includes steroid therapeutics.
• Bausch Health Companies Inc.: Known for its dermatological and other specialty products, including corticosteroids.
• Teva Pharmaceutical Industries Ltd.: A leading generic drug manufacturer with a significant presence in the steroid market.
• Merck & Co., Inc.: Another major pharmaceutical company with a diverse range of therapeutic offerings.

These companies, along with several smaller regional manufacturers, collectively supply the global demand. The market is characterized by a mix of branded and generic products. The market share is likely distributed such that companies with established manufacturing capabilities and strong distribution networks hold a significant portion. Generic competition plays a substantial role in this segment, influencing pricing and market accessibility.

What are the Primary Therapeutic Indications and Their Impact on Demand?

The demand for desoxycorticosterone acetate is directly tied to its approved therapeutic indications, predominantly related to hormonal regulation. The primary indications include:

• Adrenal Insufficiency (Addison's Disease): This is the most significant driver of DOCA demand. Addison's disease is a rare disorder where the adrenal glands do not produce enough steroid hormones. DOCA, as a mineralocorticoid, helps to replace the deficient hormone, regulating salt and water balance and preventing life-threatening complications like adrenal crisis.
• Congenital Adrenal Hyperplasia (CAH): Certain forms of CAH can involve mineralocorticoid deficiency, where DOCA may be prescribed as part of a comprehensive treatment regimen to restore electrolyte balance.
• Electrolyte Imbalances: In specific clinical scenarios, DOCA can be used to manage certain types of salt-wasting syndromes or to restore electrolyte homeostasis.

The prevalence of Addison's disease, estimated to affect approximately 1 in 100,000 people annually worldwide, forms the core demand base for DOCA [2]. While this is a rare disease, the chronic nature of the condition ensures consistent, long-term demand for effective treatments. The increasing awareness and improved diagnostic capabilities for endocrine disorders also contribute to a stable patient population requiring DOCA.

What is the Regulatory Landscape and its Influence on Market Entry and Pricing?

The regulatory landscape for desoxycorticosterone acetate is governed by national health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). As a medication with a long history of use, many DOCA products exist as generics.

Key regulatory aspects influencing the market include:

• Approval Pathways: New manufacturers seeking to enter the market with generic versions of DOCA must demonstrate bioequivalence to the reference listed drug, adhering to stringent quality and manufacturing standards. This requires extensive data submission and regulatory review.
• Good Manufacturing Practices (GMP): All manufacturers must comply with GMP regulations to ensure product safety, efficacy, and quality. Audits and inspections by regulatory bodies are routine.
• Labeling and Indication Restrictions: Regulatory approvals specify the approved indications, which limits the scope of marketing and sales efforts. Off-label use, while it may occur, is not a sanctioned driver of demand from a regulatory perspective.
• Pricing Controls: While not as heavily regulated as some other drug classes, government healthcare systems and private payers may implement formulary restrictions and reimbursement controls that influence the effective price of DOCA. Generic pricing competition is a significant factor.

The established regulatory framework means that while entry for new generic manufacturers is possible, it involves significant investment in compliance and manufacturing. For existing manufacturers, maintaining compliance is critical to continued market access.

What are the Key Patent Expirations and Their Impact on Generic Competition?

Desoxycorticosterone acetate itself is a well-established compound, meaning that its original composition of matter patents expired decades ago. The patents relevant to DOCA today would primarily pertain to:

• Formulation Patents: These may cover specific delivery systems, extended-release formulations, or novel combinations of DOCA with other active pharmaceutical ingredients.
• Manufacturing Process Patents: These could protect unique or more efficient methods of synthesizing or purifying DOCA.
• Method of Use Patents: These would cover novel therapeutic applications or treatment regimens involving DOCA that have been discovered and patented more recently.

Impact of Patent Expirations:

The expiration of original composition of matter patents has long since paved the way for generic versions of DOCA. The market is thus a mature one with significant generic penetration. Any remaining patent protection would likely be for specific advanced formulations or novel uses. The expiration of these secondary patents further opens the door for broader generic competition, potentially leading to:

• Increased Price Erosion: As more generic alternatives become available and competition intensifies, prices for DOCA tend to decrease.
• Wider Market Access: Lower prices can improve accessibility for patients and healthcare systems.
• Reduced Profit Margins for Innovators: Companies holding patents on advanced formulations or uses may see their market exclusivity diminish upon patent expiration.

A review of recent patent filings and litigations related to DOCA would reveal specific ongoing patent disputes or expirations that could impact the market in the near term. However, the fundamental patent protection for the molecule has long since lapsed.

What are the Pricing Trends and Reimbursement Policies Affecting Desoxycorticosterone Acetate?

The pricing of desoxycorticosterone acetate is influenced by several factors, including manufacturing costs, market demand, the competitive landscape of generic drugs, and reimbursement policies.

Pricing Trends:

• Generic Domination: Due to the long-standing availability of DOCA, the market is largely driven by generic products. This leads to competitive pricing, with prices generally being stable to declining, especially for established generic formulations.
• Brand vs. Generic: Branded DOCA products, if still available, would command a premium, but their market share is likely small compared to generics.
• Formulation Differences: More advanced or specialized formulations, if protected by patents, could command higher prices until those patents expire.
• Geographic Variations: Pricing can vary significantly between different countries and regions due to local market conditions, currency exchange rates, and differing healthcare systems.

Reimbursement Policies:

• Formulary Placement: Healthcare providers and insurance companies typically place DOCA on their formularies, but its position can be influenced by cost-effectiveness and the availability of therapeutically equivalent alternatives.
• Tiered Co-pays: Patients may have tiered co-payment structures, with generics generally being in lower, more affordable tiers.
• Prior Authorization: In some cases, prior authorization may be required from insurers to ensure appropriate use, particularly for higher-cost formulations or when alternatives exist.
• Government Healthcare Programs: National health services and government programs often negotiate bulk purchasing agreements or set reimbursement rates that influence the net price paid for DOCA.

The overall trend in reimbursement is towards cost containment, which favors generic drugs and can put pressure on the pricing of established medications like DOCA.

What are the Future Growth Drivers and Potential Market Risks for Desoxycorticosterone Acetate?

The future trajectory of the desoxycorticosterone acetate market is shaped by a combination of stable demand drivers and potential risks.

Growth Drivers:

• Aging Global Population: The increasing number of elderly individuals worldwide is a significant driver, as older populations have a higher incidence of conditions requiring hormonal replacement therapy, including adrenal insufficiency.
• Improved Diagnosis of Endocrine Disorders: Enhanced diagnostic tools and greater physician awareness of rare endocrine diseases like Addison's disease lead to more accurate and timely diagnoses, thereby increasing the patient pool requiring treatment.
• Niche Application Stability: The established efficacy of DOCA for its primary indications ensures consistent, albeit not explosive, demand. Its role in managing life-threatening adrenal crises provides a baseline need.
• Emerging Market Penetration: As healthcare infrastructure develops in emerging economies, access to essential medicines like DOCA may improve, leading to increased demand from these regions.

Market Risks:

• Competition from Alternative Therapies: While DOCA is a standard treatment, ongoing research in endocrinology could yield novel therapeutic agents or combination therapies for adrenal insufficiency that may offer improved efficacy, safety profiles, or convenience, potentially displacing DOCA.
• Generic Price Wars: Intense competition among generic manufacturers can lead to significant price erosion, impacting the profitability of DOCA production for all players.
• Regulatory Scrutiny and Quality Issues: Any manufacturing defects, recalls, or adverse event findings could lead to regulatory sanctions, supply disruptions, and damage to manufacturer reputations, impacting market access and demand.
• Shifting Treatment Paradigms: Advances in understanding the pathophysiology of adrenal disorders could lead to a shift in preferred treatment approaches, potentially favoring newer drug classes or different therapeutic strategies over traditional mineralocorticoid replacement.
• Limited Innovation Pipeline: The mature nature of DOCA means there is likely limited scope for significant innovation or new drug discovery directly related to the molecule, which could lead to a stagnation of market growth if not accompanied by robust demand from its established indications.

Key Takeaways

Desoxycorticosterone acetate operates in a stable, niche segment of the pharmaceutical market. Its demand is anchored by the chronic treatment needs of patients with adrenal insufficiency. The market is characterized by generic competition, leading to competitive pricing and focused efforts on manufacturing efficiency and regulatory compliance. While significant growth is not anticipated, the aging global population and improved diagnostics provide a steady demand base. Key risks include intense generic price pressure and the potential emergence of novel alternative therapies.

FAQs

1. What is the primary use of desoxycorticosterone acetate? Desoxycorticosterone acetate is primarily used to treat adrenal insufficiency, commonly known as Addison's disease, by replacing the deficient mineralocorticoid hormone. It also plays a role in managing certain electrolyte imbalances and some forms of congenital adrenal hyperplasia.

2. Is desoxycorticosterone acetate a patented drug? The original patents for the composition of matter of desoxycorticosterone acetate have long expired. Current patent protection, if any, would likely pertain to specific advanced formulations, manufacturing processes, or novel methods of use.

3. Who are the main manufacturers of desoxycorticosterone acetate? Production is concentrated among several global pharmaceutical companies, including Pfizer Inc., Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co., Inc., alongside other specialized manufacturers.

4. What is the typical price range for desoxycorticosterone acetate? As a largely generic medication, pricing is competitive and tends to be stable or declining. Specific prices vary by formulation, dosage, and geographic region, but it is generally considered an accessible treatment due to generic availability.

5. What factors could impact the future market for desoxycorticosterone acetate? Future market dynamics will be influenced by an aging global population, advancements in diagnostic capabilities for endocrine disorders, the ongoing competitive landscape of generic drugs, potential emergence of alternative therapies, and adherence to stringent regulatory standards.

Citations

[1] Grand View Research. (2023). Corticosteroids Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/corticosteroids-market

[2] American Association of Clinical Endocrinologists. (n.d.). Adrenal Insufficiency (Addison's Disease). Retrieved from https://www.aace.com/patients/disease-states/adrenal-insufficiency-addison%E2%80%99s-disease